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increase levels of HBV DNA or cccDNA. TAF or ETV inhibited HIV-1
RNA replication in co-cultured and coinfected cells. TAF, ETV or GLP-
26 similarly inhibited HBV DNA replication in HepAD38 cells mono-
or -cocultured with CD4+T cells, with or without HIV-1. GLP-26 in the
presence or absence of HIV-1 inhibited HBV DNA replication more
potently than TAF or ETV, with EC90 values 3- to 7-fold lower for GLP-
26 versus TAF or ETV.
Figure 1: Immunofluorescence image of 3D co-cultured HepAD38 plus
CD4+T cells co-infected with HIV-1.
Conclusions: Organoids contained HBV (HepAD38 or HepG2-NTCP)
andHIV-1 (CD4+T) permissive cells supported productive HBV and/or
HIV-1 replication. This novel model was reproducible and provided
multiple and simultaneous modalities to quantify HIV-1 and HBV
replication; this system can be used to measure key cellular events
that drive pathogenesis of HIV-1/HBV in co-infected individuals, and
can also be used to identify novel agents that block these events in the
context of a relevant cellular system of co-infection. More import-
antly, we validated this novel organoid system of co-infection as a
model for HBV infection and antiviral evaluation.
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Background and Aims: Switching to TAF, a novel tenofovir prodrug,
has shownmaintenance of viral suppressionwith stable or improved
bone and renal safety atWk 24 in CHB patients with impaired hepatic
function. Here we evaluated the efficacy and safety 48 weeks after
CHB patients with hepatic decompensation were switched to TAF.
Method: In this Phase 2 study (NCT03180619) patients with CHB
having a Child–Turcotte–Pugh (CTP) score≥7 and≤12 at screening, or
by documented history, receiving TDF and/or other OAVs for ≥48
weeks, with HBV DNA <LLOQ for ≥24 weeks and <20 IU/mL at
screening were eligible to participate. All patients were switched to
TAF25 mgQDandwere tobe treated for 96weeks. Safetyassessments
including changes in bone (hip and spine BMD) and renal (CrCl by
Cockcroft-Gault [eGFRCG], serum creatinine) parameters, viral sup-
pression, and biochemical responses were assessed at Week 48.
Results: 31 patients were enrolled at 18 sites in 7 countries and 90%
completed 48 weeks of treatment. At baseline, 74% were ≥50 y, 68%
male, 81% Asian, 90% HBeAg-negative, with median fibrotest (FT)
score 0.81, median CTP and MELD scores of 6 and 10, respectively,
median eGFRCG 98 mL/min, and 19% and had osteoporosis by T score
at spine. Prior use of TDF and entecavir was reported by 68% and 45%,
respectively. Keyefficacy/safety results atWeek 48 are summarized in
the Table. By missing equals failure analysis, 31 patients (100%) had
HBV DNA <20 IU/mL, 81% had normal ALTand CTP/MELD scores were
stable. After switching to TAF in this population with liver
impairment, CTP, MELD, and FT scores were unchanged while bone
and renal parameters were stable. TAF was well tolerated with few
having Grade 3 or 4 AEs (4 patients); no serious AEs related to study
drug, and 1 patient who discontinued for worsening renal function
unrelated to TAF.
Conclusion: CHB patients with hepatic impairment who were
switched to TAF from TDF or other OAV showed high rates of viral
suppression, normal ALT and bone and renal safety were stable at
Week 48.
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Background and Aims: European clinical practice guidelines (EASL)
on chronic hepatitis B recently recognized the importance of
migration flows in changing the prevalence and incidence of hepatitis
B infection in low endemic European countries such as Italy and
Germany. Phylogenetic analyses have shown that genotype E, which
is mainly diffused in West Africa, is relatively recent. No data were
available about a different serological or virological response in naïve
patients affected by chronic hepatitis B (CHB), E genotype treated
with tenofovir (TDF) or ETV. The aimof this studywas the prospective
evaluation of serological and virological response in a cohort of CHB
patients with E genotype treated with TDF or ETV and followed for at
least 5 years.
Method: we prospectively evaluated qHBsAg decline in chronic
hepatitis B, HBeAg-negative, E genotype, treated with tenofovir
245 mg (TDF) or ETV 0.5 mg from 2008 to 2014. Inclusion criteria
were: naïve patients with active chronic hepatitis B (CHB) without
other viral co-infection. qHBsAg test was performedwith ARCHITECT
HBsAg (Abbott Diagnostics, Ireland). Serum HBV-DNA levels were
quantified by the Real Time PCR COBAS AmpliPrep/COBAS TaqMan
HBV Test 2.0 (Roche Molecular Systems, NJ, USA).
Results: sixty-five patients (89.2% males) were enrolled. Median age
was 29 years [IQR 22–36] and the most prevalent route of
transmission was familiar (25; 38.5%). Median liver stiffness was
7.4 kPa [IQR 4.5–9.3], ALT 65 U/L [IQR 31–122], HBV-DNA 3.4Log IU/
ml [IQR 2.8–4.5], qHBsAg3.4Log UI/ml [IQR 2.8–4.5]. According to
clinical evaluation, 40 patients (61.5%) started ETV whereas 25
POSTER PRESENTATIONS
S872 Journal of Hepatology 2020 vol. 73 | S653–S915
patients (38.5%) TDF. The qHBsAg decline was significantly higher in
patients treated with TDF at any time-points and after 5 years the
median declinewith ETVwas 0.31 LogIU/mL and 0.68 LogIU/mLwith
TDF. At the same time-points higher response rate in HBV-DNA
suppression were observed in patients receiving TDF. In the absence
of resistance-associated mutations, in 20% of ETV-patients HBV-DNA
persisted detectable at 5 years. In univariate analysis for qHBsAg
decline the following factors were considered: age, sex, qHBsAg and
HBV-DNA at baseline, liver stiffness, type of therapy. In the
multivariate analysis the only predictive factor for qHBsAg decline
is the treatment with TDF (β = − 0.119; DS = 0.025; p < 0.001).
Figure: qHBsAg decline after 5 years of therapy in patients affected by
CHB and treated with ETV or TDF.
Conclusion: in E genotype the patients treated with TDF showed
greater qHBsAg decrease after 5 years than ETV; virological response
was higher in TDF than ETV groups. The reason of this finding was
unknown and further studies are required to explain this aspect.
According to our results, however, TDF could represent the optimal
choice in this setting of patients.
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Background and Aims: Sustained response is observed in a limited
number of patients after cessation of nucleo(s)tide analogue (NA)
therapy. We aimed to study the relationship between serum levels of
hepatitis B core related antigen (HBcrAg) and HBsAg at treatment
Figure: (abstract: SAT442)
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